U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07564596) titled 'A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)' on April 27.
Brief Summary: Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity. This Phase 1b/2a, open-label study will evaluate budoprutug in ascending dose cohorts of patients aged 18 years and above with active, seropositive SLE and inadequate response to standard therapy. The study will also assess the pharmacokinetics, pharmacodynamics and early indications of efficacy of budoprutug in SLE, where pharmacodynamics will ...